Agilent (A) announced that its MMR IHC Panel pharmDx has received class C companion diagnostic certification under EU in vitro diagnostic regulation as a CDx test for colorectal cancer. MMR IHC Panel pharmDx is indicated as an aid to identify mismatch repair deficient CRC patients eligible for treatment with Opdivo in combination with Yervoy. MMR IHC Panel pharmDx is approved for exclusive use with the Agilent Dako Omnis automated staining solution.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent Technologies Surpasses Expectations in Q3 Earnings Call
- Agilent Technologies Grapples with Regulatory and Sustainability Challenges Impacting Financial Stability
- Early notable gainers among liquid option names on August 28th
- Agilent price target raised to $142 from $141 at Baird
- Agilent’s Strong Revenue Growth Offset by Margin Concerns: Hold Rating Maintained